The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
Activity Number:
|
192
|
Type:
|
Roundtables
|
Date/Time:
|
Monday, August 1, 2011 : 12:30 PM to 1:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #300818 |
Title:
|
Effect of Subsequent Therapies After Discontinuation of Study Medication in Analyzing Overall Survival in Cancer Clinical Trials
|
Author(s):
|
Julie Xiuyu Cong*+
|
Companies:
|
Boehringer Ingelheim
|
Address:
|
900 Ridgebury Rd, Ridgefield, CT, 06877, USA
|
Keywords:
|
Subsequent treatment/therapy ;
treatment discontinuation ;
overall survival ;
clinical trials ;
cancer/oncology
|
Abstract:
|
Typically in cancer trials, patients are discontinued from the randomized study medication (control or experimental treatment) if patients develop disease progression or intolerable adverse events. In many cancer settings, such patients continue living for a considerably long time and take other anti-cancer therapies available to them. These patients are typically followed up for vital status in the trial with the aim to evaluate overall survival. As a result of such subsequent therapies, the treatment effect of true interest (experimental vs. control) is not properly assessed using the standard Intent-to-Treat (ITT) approach. Various statistical methodologies have been proposed and investigated by statisticians worldwide, including but not limited to marginal structural model, nested structural model, propensity scores, etc. This roundtable session aims to discuss the pros and cons of available methodologies and stimulate new ideas.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.